Predicting factor for HER-2 gene status in immunohistochemistry-equivocal (2+) breast cancer

被引：0
|
作者：
Kim, S. K. [1 ]
Kang, S. Y. [1 ]
Youn, H. J. [1 ]
Jung, S. H. [1 ]
机构：
[1] Jeonbuk Natl Univ Hosp, Surg, Jeonju, South Korea
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)70151-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P107
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [1] Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer
    Ji, Yongling
    Sheng, Liming
    Du, Xianghui
    Qiu, Guoqin
    Chen, Bo
    Wang, Xiaojia
    JOURNAL OF THORACIC DISEASE, 2014, 6 (07) : 896 - 904
  • [2] The role of HER2 gene copy number variations in immunohistochemistry-equivocal (2+) breast cancer
    Kocsmar, I.
    Tokes, A. M.
    Kafer, D.
    Kocsmar, E.
    Kristof, K. Attila
    Kulka, J.
    Lotz, G.
    VIRCHOWS ARCHIV, 2020, 477 : S225 - S225
  • [3] Correlation of immunohistochemistry-equivocal (2+) human epidermal growth factor receptor 2 (HER2) with fluorescence in situ hybridization (FISH) gene status in invasive breast cancer: Is FISH necessary for all HER2 equivocal breast cancer cases?
    Alswayyed, Mohammed
    KUWAIT MEDICAL JOURNAL, 2022, 54 (04): : 476 - 480
  • [4] Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining
    Mostafa, Naglaa A. E.
    Eissa, Saad S.
    Belal, Dalia M.
    Shoman, Soheir H.
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2011, 23 (01) : 41 - 46
  • [5] Percentage of Her2 positive cells in immunohistochemistry-equivocal (2+) invasive breast cancer and its significance as a predictive value for the amplification status
    Marras, V.
    Satta, G.
    Fedeli, M. A.
    Trombetta, M.
    Lako, K.
    Meloni, M.
    Fara, A. M.
    Camboni, A. C.
    Doneddu, V.
    Manca, A.
    Tanda, F.
    VIRCHOWS ARCHIV, 2017, 471 : S58 - S58
  • [6] Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining
    Lewis, JT
    Ketterling, RP
    Halling, KC
    Reynolds, C
    Jenkins, RB
    Visscher, DW
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 124 (02) : 273 - 281
  • [7] Equivocal (2+) HER-2/neu results by immunohistochemistry in breast carcinoma: "normalizing" reduces need for FISH testing
    Santiano, Estrella J.
    Salvatore, P. S.
    Hoda, A. S.
    VIRCHOWS ARCHIV, 2009, 455 : 192 - 192
  • [8] Using Machine Learning to Predict Final HER2 Status in Invasive Breast Cancer Cases that are Equivocal (2+) by Immunohistochemistry
    Rasmussen, Sean
    Taylor, Valerie
    Surette, Alexi
    Barnes, Penny
    Bethune, Gillian
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 182 - 182
  • [9] Using Machine Learning to Predict Final HER2 Status in Invasive Breast Cancer Cases that are Equivocal (2+) by Immunohistochemistry
    Rasmussen, Sean
    Taylor, Valerie
    Surette, Alexi
    Barnes, Penny
    Bethune, Gillian
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 182 - 182
  • [10] Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients
    Gheybi, Mohammad Kazzem
    Baradaran, Azar
    Mohajeri, Mohammad Reza
    Ostovar, Afshin
    Hajalikhani, Parvaneh
    Farrokhi, Shokrollah
    APMIS, 2016, 124 (05) : 365 - 371
12345